The rationale for targeting PD-1/PD-L1 signaling in cHL stems from the overexpression of PD-L1 on HRS cells and the presence of PD-1-expressing exhausted T cells within the tumor microenvironment. The gene discussed is CD274; the disease is classic Hodgkin lymphoma.